Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic Absorption of MOB015B in Onychomycosis
NCT03244280Phase 1Completed
- Sponsor
- Moberg Pharma AB
- Start
- Dec 2017
- Primary completion
- Apr 2018
- Modality
- Transdermal Patches, Orthosteric Ligands, Hydrogel Systems
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MOB-015 in onychomycosis, sponsored by Moberg Pharma AB. Primary endpoints: Maximum Plasma Concentration at 28 days, Time to Maximum Plasma Concentration at 28 days and 1 more. Started Dec 2017; status: completed.
02
Drugs
MOB-015
03
Conditions
onychomycosis
Beyond the preview
Go deeper on NCT03244280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03244280.